China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-06-17	2.220 $	-4.31%	70,768
26-06-16	2.320 $	-1.28%	16,371
26-06-15	2.350 $	-8.56%	86,274
26-06-12	2.570 $	+13.72%	162,508
26-06-11	2.260 $	+28.41%	1,156,656

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-17 EDT			5-day change	1st Jan Change
2.220 ^USD	-4.31%		+26.14%	-99.07%

01-08	Top Midday Gainers	MT
12-31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI

Market Cap	1.43M 1.24M 1.14M 1.07M 2.01M 135M 2.03M 13.48M 5.25M 66.41M 5.38M 5.27M 230M	P/E 2024 *	-	P/E 2025	-
Enterprise Value	-15.82M -13.65M -12.55M -11.81M -22.19M -1.49B -22.38M -149M -57.89M -733M -59.37M -58.1M -2.53B	EV / Sales 2024	-3.85x	EV / Sales 2025	9.81x
Free-Float	99.29%	Yield 2024 *	-	Yield 2025	-

01-08	Top Midday Gainers	MT
12-31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
25-07-31	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
25-03-28	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024	CI
25-03-17	China Sxt Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Requirement	MT
25-01-23	China SXT Pharmaceuticals, Inc. Announces CEO Changes	CI
25-01-23	China SXT Pharmaceuticals, Inc. Announces Board and Committee Changes	CI
25-01-20	China SXT Pharmaceuticals, Inc. announced that it expects to receive $2.84 million in funding	CI
24-08-13	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	CI
24-08-12	China SXT Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-05-12	China SXT Pharmaceuticals, Inc. announced that it has received $0.75 million in funding from Streeterville Capital, LLC	CI
24-05-08	China SXT Pharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding from Streeterville Capital, LLC	CI
24-04-05	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	CI

03-24	China SXT Pharmaceuticals, Inc. Announces Share Re-classification	AQ
01-30	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ
01-15	CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN	AQ
01-13	Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)	AQ
01-09	China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering	AQ

China SXT Pharmaceuticals, Inc. Stock

Stocks

SXTC

VGG2161P1650

Pharmaceuticals

Valuation: China SXT Pharmaceuticals, Inc.

Chart: China SXT Pharmaceuticals, Inc.

Latest news : China SXT Pharmaceuticals, Inc.

Press Releases: China SXT Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: China SXT Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-4.31%
1 week	+26.14%
Current month	+32.93%
1 month	+40.51%
3 months	+23.33%
6 months	-99.06%
Current year	-99.07%

1 week	2.16	2.77
1 month	1.41	2.77
Current year	1.25	1,046.98
1 year	1.25	1,046.98
3 years	1.25	11,249.94
5 years	1.25	1,000,000
10 years	1.25	1,000,000

Manager	Title	Age	Since
Sze Beng Lim CEO	Chief Executive Officer	-	2025-01-19
Feng Zhou CEO	Chief Executive Officer	34	2017-07-03
Xiaodong Pan DFI	Director of Finance/CFO	49	2022-01-30

Director	Title	Age	Since
Feng Zhou CHM	Chairman	34	2017-07-03
Jun Zheng BRD	Director/Board Member	49	2018-12-30
Xiaodong Ji BRD	Director/Board Member	57	2021-05-21

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA SXT PHARMACEUTICALS, INC.	-4.31%	+26.14%	-99.20%	-99.97%	14.34M
ELI LILLY AND COMPANY	-0.94%	-2.14%	+40.54%	+148.38%	992B
JOHNSON & JOHNSON	-0.42%	-1.80%	+53.69%	+42.60%	564B
ABBVIE INC.	-0.56%	-1.65%	+19.27%	+59.57%	391B
ROCHE HOLDING AG	-0.40%	+0.68%	+24.66%	+16.53%	330B
ASTRAZENECA PLC	-0.40%	-1.22%	+27.15%	+15.16%	280B
NOVARTIS AG	-0.56%	-1.02%	+26.67%	+32.42%	279B
NOVO NORDISK A/S	-0.83%	-0.02%	-41.45%	-47.82%	196B
AMGEN INC.	-1.78%	+1.16%	+17.79%	+48.77%	184B
GILEAD SCIENCES, INC.	-1.40%	+3.27%	+16.16%	+59.08%	156B
Average	-0.68%	+2.98%	+8.53%	+27.47%	337.12B
Weighted average by Cap.	-0.08%	-0.49%	+29.32%	+65.85%

	2024	2025
Net sales	1.93M 1.66M 1.53M 1.44M 2.71M 182M 2.73M 18.13M 7.06M 89.32M 7.24M 7.08M 309M	1.74M 1.5M 1.38M 1.3M 2.44M 164M 2.46M 16.36M 6.37M 80.63M 6.53M 6.39M 279M
Net income	-3.1M -2.67M -2.46M -2.31M -4.35M -292M -4.38M -29.12M -11.34M -144M -11.63M -11.38M -496M	-3.3M -2.85M -2.62M -2.47M -4.63M -312M -4.67M -31.05M -12.09M -153M -12.4M -12.13M -529M
Net Debt	-8.38M -7.23M -6.64M -6.25M -11.75M -790M -11.85M -78.72M -30.65M -388M -31.43M -30.76M -1.34B	-17.25M -14.88M -13.68M -12.88M -24.2M -1.63B -24.41M -162M -63.14M -799M -64.75M -63.37M -2.76B